Immix Biopharma, Inc

75 articles about Immix Biopharma, Inc

• Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors

  6/20/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective , Jeffrey H. Cooper, former Chief Financial Officer of BioMarin Pharmaceutical Inc., has been appointed to the Company’s Board of Directors.

• Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors

  6/16/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective , Mary Sue Coleman, former Independent Director of Johnson & Johnson, has been appointed to the Company’s Board of Directors.

• Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors

  6/12/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective today, Henry A. McKinnell, Jr, Ph.D., former Chairman and Chief Executive Officer of Pfizer Inc., has been appointed to the Company’s Board of Directors.

• Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site

  5/26/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced the commencement of CAR-T NXC-201 Engineering Batches at its U.S. Manufacturing Site. These U.S. engineering batches will support the planned U.S. expansion of the Company’s ongoing Phase 1b/2a NEXICART-1 study of its novel BCMA-targeted chimeric antigen receptor T cell therapy NXC-201.

• Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

  5/21/2023

  Immix Biopharma, Inc., announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its novel, autologous, BCMA-targeted chimeric antigen receptor T cell therapy NXC-201 for the treatment of patients with relapsed or refractory multiple myeloma and light chain amyloidosis.

• Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

  5/4/2023

  Immix Biopharma, Inc. announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy to be held in Los Angeles May 16-20, 2023.

• Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting

  4/4/2023

  Nexcella Inc., a subsidiary of Immix Biopharma, Inc. announced that updated NXC-201 clinical data has been selected to be presented at the upcoming 49th annual meeting of the European Society for Blood and Marrow Transplantation to be held in Paris, France, 23-26 April 2023.

• Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential

  3/23/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. announced that NXC-201 treatment continues to demonstrate 100% complete hematologic responses and 100% organ response rate – cardiac, renal, liver response – in a total of 8 AL amyloidosis patients.

• Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank

  3/11/2023

  Immix Biopharma, Inc., a biopharmaceutical company pioneering Tissue-Specific Therapeutics ™ targeting oncology and immuno-dysregulated diseases, confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank or Silvergate Bank.

• ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14

  3/6/2023

  Immix Biopharma, Inc. and its subsidiary Nexcella, Inc. (“Nexcella”) today announced that Ilya Rachman, M.D., Ph.D., ImmixBio Chief Executive Officer, and Gabriel Morris, Nexcella President, will discuss recent positive NXC-201 clinical data in AL Amyloidosis and Multiple Myeloma in a fireside chat at the 35th Annual Roth Conference on Tuesday, March 14, 2023 at 10:30 a.m. PT.

• Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.

  2/15/2023

  Nexcella, Inc. (“Nexcella”, “Company”) today announced that it has entered into a manufacturing agreement with a well-known United States Good Manufacturing Practice (GMP) cell therapy manufacturer that will supply a US Phase 1b/2 clinical trial of NXC-201 in relapsed/refractory multiple myeloma and AL amyloidosis.

• Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer

  2/7/2023

  Immix Biopharma, Inc. today announced dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab Combination Phase 1b/2a Clinical Trial in patients with advanced solid tumors.

• Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

  1/13/2023

  Immix Biopharma, Inc. today announced dosing of an additional patient in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. 

• Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached

  1/6/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that NXC-201 treatment continues to demonstrate 100% complete responses in a total of 6 relapsed/refractory AL amyloidosis patients.

• Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting

  12/28/2022

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. announced that updated NXC-201 clinical data has been selected to be presented at the upcoming European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting to be held in Rotterdam, Netherlands February 9-11, 2023.

• Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

  12/20/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced another patient was dosed in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. This is the sixteenth patient dosed with IMX-110 to-date, and the second patient dosed so far in December 2022.

• ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors

  12/19/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it has shipped Good Manufacturing Practice (“GMP”) manufactured batches of Tislelizumab for clinical trial patient dosing.

• Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)

  12/14/2022

  Immix Biopharma, Inc. announced that it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 with 85% overall response rate and 71% complete response/stringent complete response at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial as of June 27, 2022 data cutoff with a median of 6 prior lines of therapy.

• Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

  12/13/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced patient dosing in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial.

• ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing

  12/12/2022

  Immix Biopharma, Inc. announced that it has completed release testing and shipped Good Manufacturing Practice process manufactured batches of IMX-110 for clinical trial patient dosing.